Multiple sclerosis or MS is a disease that affects the brain and spinal cord resulting in loss of muscle control, vision, balance, and sensation (such as numbness). With MS, the nerves of the brain and spinal cord are damaged by one's own immune system. Thus, the condition is called an autoimmune disease.
Autoimmune diseases are those whereby the body's immune system, which normally targets and destroys substances foreign to the body such as bacteria, mistakenly attacks normal tissues. In MS, the immune system attacks the brain and spinal cord, the two components of the central nervous system. Other autoimmune diseases include lupus and rheumatoid arthritis.
The central nervous system is made up of nerves that act as the body's messenger system. Each nerve is covered by a fatty substance called myelin, which insulates the nerves and helps in the transmission of nerve impulses, or messages, between the brain and other parts of the body. These messages control muscle movements, such as walking and talking.
MS gets its name from the buildup of scar tissue (sclerosis) in the brain and/or spinal cord. The scar tissue or plaques form when the protective and insulating myelin covering the nerves is destroyed, a process called demyelination. Without the myelin, electrical signals transmitted throughout the brain and spinal cord are disrupted or halted. The brain then becomes unable to send and to receive messages. It is this breakdown of communication that causes the symptoms of MS.
Although the nerves can regain myelin, this process is not fast enough to outpace the deterioration that occurs in MS. The types of symptoms, severity of symptoms, and the course of MS vary widely, partly due to the location of the scar tissue and the extent of demyelination.
According to the National Multiple Sclerosis Society, the condition affects approximately 400,000 Americans and is, with the exception of trauma, the most frequent cause of neurological disability beginning in early to middle adulthood.
MS is two to three times as common in females as in males and its occurrence is unusual before adolescence. A person has an increased risk of developing the disease from the teen years to age 50 with the risk gradually declining thereafter.
Proteolytic Enzymes and Their Effectiveness for MS
Research has shown the effectiveness of using proteolytic enzyme preparations to treat the inflammatory process responsible for the myelin sheath damage that characterizes Serracor-NK , SerraRX80 and other proteolytic enzymes are substances that cleave proteins.
In MS, the myelin protective sheath that covers the nerve cells is broken down by immune complexes that are embedded in it. Serracor-NK,Serrra RX80 and other proteolytic enzymes break down the destructive immune complexes and can dramatically reduce MS symptoms. While regeneration of damaged tissue is not possible, regular supplementation with enzymes has been documented to halt the progress of degeneration associated with most stages of MS.
In addition to the localized effect on the immune complexes embedded in the myelin, there are several other benefits of proteolytic enzyme supplementation:
Their anti-inflammatory action works on all circulating immune complexes, not just the ones in the myelin. This action reduces inflammation in all soft and connective tissues of the body such as internal organs, eyes, skin, muscles, tendons, fascia, joint capsules, blood vessels, etc. All of these various tissues benefit from the reduction of inflammation.
They are anti-fibrotic, meaning that they break down hard, fibrotic tissue, and in so doing, help prevent atherosclerotic plaqueing, hypertension and other cardiovascular diseases, thrombosis, blood clots, uterine fibroids and other fibromas, fibrocystic breasts and other fibrous degeneration.
They are blood-thinning. Like aspirin, proteolytic enzymes lower blood viscosity. Unlike aspirin, enzymes present no risk of hemorrhage (the blood becoming too thin) and cause no complications from gastrointestinal bleeding. The mechanisms by which the thinning occurs involves the breaking down and cleaning up of waste products, cellular debris, circulating immune complexes, and white blood cells. By cleaning up the blood, more white blood cells are made available to protect the body from new intruders.
How can Serracor-NK and SerraRX80 Help? Using a systemic enzyme approach helps immensely as it clears out all of the inflammation and dead/scar tissue, restores a healthy digestive system and provides all of the nutrients to repair the damaged tissue. By clearing away this problem tissue, it enables the nerve signal to work unimpeded and possibly the body's own healing system to replace it with healthy tissue.
Promotes healthy circulation by reducing excessive fibrin levels and reducing blood viscosity.*
Lowers C-Reactive Protein levels in blood.*
Supports a healthy inflammatory response and the natural healing process.*
Combines two enterically coated, fibrinolytic proteases, Peptizyme SP® (Serrapeptase) and NattoSEB®(Nattokinase) that specifically address fibrin levels in the body.*
BIOMEDIC LABS, LLC Since 2004 Scientifically Advanced Supplements
*The products and the claims made about specific products on or through this site have not been evaluated by the United States Food and Drug Administration and are not intended to diagnose, treat, cure or prevent disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. Please view our full Terms Of Use Agreement for more information and the terms and conditions governing your use of this site.
